Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1999 1
2001 2
2002 1
2004 2
2005 2
2006 5
2008 1
2010 1
2011 4
2012 2
2013 1
2015 1
2017 1
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ. Moss DJH, et al. Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Lancet Neurol. 2017. PMID: 28642124
BACKGROUND: Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. ...We generated a parallel progression score using data from 1773 previously genotyped participants from the European Huntington's Disease Network REGISTRY study of …
BACKGROUND: Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. ...We generated a parallel progress …
Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study.
McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network. McNulty P, et al. J Huntingtons Dis. 2018;7(3):209-222. doi: 10.3233/JHD-170263. J Huntingtons Dis. 2018. PMID: 30103338
BACKGROUND: People with Huntington's disease (HD) have been observed to have lower rates of cancers. OBJECTIVE: To investigate the relationship between age of onset of HD, CAG repeat length, and cancer diagnosis. METHODS: Data were obtained from the European Huntington
BACKGROUND: People with Huntington's disease (HD) have been observed to have lower rates of cancers. OBJECTIVE: To investigate the re …
Huntington's disease: present treatments and future therapeutic modalities.
Bonelli RM, Wenning GK, Kapfhammer HP. Bonelli RM, et al. Int Clin Psychopharmacol. 2004 Mar;19(2):51-62. doi: 10.1097/00004850-200403000-00001. Int Clin Psychopharmacol. 2004. PMID: 15076012 Review.
Huntington's disease (HD) is a devastating neuropsychiatric disorder for which therapeutic interventions have been rather fruitless to date, except in a slight symptomatic relief. ...
Huntington's disease (HD) is a devastating neuropsychiatric disorder for which therapeutic interventions have been rather fruitless t
Pharmacological management of Huntington's disease: an evidence-based review.
Bonelli RM, Wenning GK. Bonelli RM, et al. Curr Pharm Des. 2006;12(21):2701-20. doi: 10.2174/138161206777698693. Curr Pharm Des. 2006. PMID: 16842168 Review.
INTRODUCTION: Despite the increasing body of published reports on pharmacological interventions in Huntington's disease (HD), an evidence based review (EBR) of treatment studies has not yet been published. ...
INTRODUCTION: Despite the increasing body of published reports on pharmacological interventions in Huntington's disease (HD), an evid …
Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.
Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Orth M, et al. J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1409-12. doi: 10.1136/jnnp.2010.209668. Epub 2010 Nov 19. J Neurol Neurosurg Psychiatry. 2011. PMID: 21097549 No abstract available.
Diffusion-weighted imaging in Huntington's disease.
Seppi K, Schocke MF, Mair KJ, Esterhammer R, Weirich-Schwaiger H, Utermann B, Egger K, Brenneis C, Granata R, Boesch S, Poewe W, Wenning GK. Seppi K, et al. Mov Disord. 2006 Jul;21(7):1043-7. doi: 10.1002/mds.20868. Mov Disord. 2006. PMID: 16570300
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder that results from an expanded trinucleotide (CAG) repeat on the huntingtin gene. ...
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder that results from an expanded trinucleotide
Seminar on choreas.
Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Cardoso F, et al. Lancet Neurol. 2006 Jul;5(7):589-602. doi: 10.1016/S1474-4422(06)70494-X. Lancet Neurol. 2006. PMID: 16781989 Review.
Diagnostic work-up can be straightforward in patients with a positive family history of Huntington's disease or acute-onset hemichorea in patients with lacunar stroke, but it can be a challenging and complex task in rare autoimmune or genetic choreas. Principles of managem …
Diagnostic work-up can be straightforward in patients with a positive family history of Huntington's disease or acute-onset hemichore …
Suicidal ideation in a European Huntington's disease population.
Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington's Disease Network. Hubers AA, et al. J Affect Disord. 2013 Oct;151(1):248-58. doi: 10.1016/j.jad.2013.06.001. Epub 2013 Jul 20. J Affect Disord. 2013. PMID: 23876196 Free article.
BACKGROUND: Previous studies indicate increased prevalences of suicidal ideation, suicide attempts, and completed suicide in Huntington's disease (HD) compared with the general population. This study investigates correlates and predictors of suicidal ideation in HD. METHOD …
BACKGROUND: Previous studies indicate increased prevalences of suicidal ideation, suicide attempts, and completed suicide in Huntington
Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
Cubo E, González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán JM; European Huntington's Disease Initiative Study Group. Cubo E, et al. Mov Disord. 2012 Mar;27(3):439-42. doi: 10.1002/mds.24062. Epub 2011 Dec 9. Mov Disord. 2012. PMID: 22162184
BACKGROUND: Classically, clinical trials are based on the placebo-control design. Our aim was to analyze the placebo effect in Huntington's disease. METHODS: Placebo data were obtained from an international, longitudinal, placebo-controlled trial for Huntington's di …
BACKGROUND: Classically, clinical trials are based on the placebo-control design. Our aim was to analyze the placebo effect in Huntington
Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T; EHDI Study Group, Roos RA. Aziz NA, et al. Neurology. 2008 Nov 4;71(19):1506-13. doi: 10.1212/01.wnl.0000334276.09729.0e. Neurology. 2008. PMID: 18981372 Clinical Trial.
OBJECTIVE: Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded number of CAG repeats in the huntingtin gene. ...Similarly, R6/2 mice with a larger CAG repeat length had a lower body weight, whereas caloric intake increased with larger C …
OBJECTIVE: Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded number of CAG repeats in the hunt …
22 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback